1. Introduction {#sec1}
===============

*Rhodococcus equi*(*R. equi*) is a Gram-positive, nonmotile, obligate aerobe, intracellular microorganism. Virulent*R. equi*causes pyogranulomatous bronchopneumonia in young foals aged from 1 to 6 months \[[@B1]\]. Young foals may also develop extrapulmonary disease, such as septic arthritis, osteomyelitis, ulcerative enterocolitis, mesenteric lymphadenopathy, neonatal diarrhea, and sudden death.*R. equi* is additionally considered as an opportunistic pathogen of immunosuppressed people, especially AIDS patients \[[@B2]\].*R. equi*was initially isolated from pulmonary lesions of foals by Magnusson in 1923 \[[@B3]\].*R. equi* bacterium is present in soil and horse feces. Foals are thought to become infected when, within the first few days of life, they ingest or breathe in soil, dust, or fecal particles harboring the bacteria \[[@B2], [@B4]\]. Inhalation of aerosolized virulent*R. equi* from the environment and intracellular replication within alveolar macrophages is essential components of pathogenesis of*R. equi* pneumonia in foals \[[@B5]\]. Virulence in foals is associated with the presence of 80--90 kb plasmids that encode the 15--17 kDa lipoprotein "virulence-associated protein A" (VapA) \[[@B6]\]. The disease is endemic on some farms and sporadic on other farms, but nonexistent on most farms. Recent epidemiologic studies indicate that the difference in the disease\'s prevalence on farms directly relates to differences in foal population density, farm management, and environmental factors, such as temperature, dust, soil pH, and the number of virulent*R. equi*organisms in the soil \[[@B7]\].

Several antimicrobial agents are active against*R. equi*in vitro. However, since*R. equi*is a facultative intracellular pathogen that survives, replicates in macrophages, and causes pyogranulomatous lesions, many of these agents are ineffective in vivo \[[@B8]\].*R. equi*pneumonia significantly impacts the equine industry by posing financial losses since foals that recover from the disease are less likely to race as adults. The cost of therapy and occasional death of foals also pose financial risks. Furthermore, treatment with long-term antibiotics does not guarantee full recovery \[[@B9]\].

Due to the epitheliochorial placentation of equines, foals must obtain all maternally derived antibodies from the ingestion of colostrum \[[@B10]\]. Ingestion of colostrum from hyperimmunized mares was found to be associated with protection against*R. equi* in foals normally hypogammaglobulinemic at birth \[[@B11], [@B12]\]. Foals become infected approximately when maternal antibody concentrations wane \[[@B13]\]. Immunization of mares has been suggested by several researchers to prevent*R. equi* infection in foals \[[@B11], [@B12], [@B14]--[@B17]\]. Traditional hyperimmune plasma therapy is currently the only proven method for prevention of*R. equi* in foals, especially those exhibiting passive antibody transfer failure \[[@B11], [@B12], [@B15]\].

Due to the presence of the maternal antibody and the immaturity of foals\' immune system, vaccination of neonate presents different results \[[@B18]--[@B20]\], yet none of the control strategies to protect horses from*R. equi* infection have proven successful. Several vaccines have been investigated for the prevention of*R. equi*, though none have been developed for widespread vaccination \[[@B21]\].

This study thus aimed to determine the effectiveness of a pregnant mare immunization with a*R. equi* vaccine candidate and the administration of anti-*R. equi* hyperimmune plasma against*R. equi* challenge in these mares\' foals.

2. Materials and Methods {#sec2}
========================

2.1. Immunization of Mares {#sec2.1}
--------------------------

Four pregnant thoroughbred Arabian mares were vaccinated three times at months 8, 9, and 10 during pregnancy. Vaccination was performed intramuscularly with the*R. equi* vaccine candidate containing a water-based nanoparticle mineral oil adjuvanted (IMS 3012, SEPPIC, Paris, France) inactive antigen and VapA. Four mares not vaccinated formed the control group. Serum samples were collected from each mare at birth to test the presence of an anti-*R. equi*-specific antibody by ELISA. ELISA was carried out according to Takai et al. \[[@B22]\].

Nine healthy Arabian mares were selected for the production of anti-*R. equi* hyperimmune plasma. After proving to be free of equine infectious anemia (EIA), dourine, glanders, African horse sickness, and*S. abortus equi*, the mares were hyperimmunized 5 days apart with four doses of inactive*R. equi*. After 10 to 15 days, mares were vaccinated 21 days apart with 3 doses of*R. equi* vaccine candidate \[[@B23], [@B24]\]. After 15 to 20 days following the most previous immunization, serum samples were obtained from the mares and tested by ELISA for anti-*R. equi* antibody titers \[[@B22]\]. Horses having anti-*R. equi* antibody titers ≥1/12800 by ELISA were selected as plasma donors. Donor horses were bled, and the hyperimmune plasma was separated from the blood cells by plasmapheresis (PCS2, Haemonetics, Braintree, MA, USA). The plasma samples were packed in 200 mL sterile bottles in a BSL 2 cabinet and stored at 4°C. Sterility tests for aerobic, anaerobic bacteria, mycoplasma, and mycotic agents as well as mouse safety tests were performed, after which the hyperimmune plasma samples were used. Donor horses were subsequently vaccinated at intervals of 50 to 60 days and tested 10 to 15 days later, and if the titers were again satisfactory, they were again bled.

2.2. Challenge {#sec2.2}
--------------

To determine the effectiveness of a pregnant mare immunization using a*R. equi* vaccine candidate and HI plasma activity against*R. equi* infection in foals, 4 weeks old mares which born four vaccinated and four unvaccinated mares challenged the 2 mL of 1.0 × 10^5^ CFU pathogen*R. equi* by intercostal injection in the lobe of the left lung \[[@B25], [@B26]\]. Before receiving the challenge, foals were kept together with their dams approximately 3 weeks after birth to ingest a sufficient amount of colostrum. Two days before the challenge, 150 mL of HI plasma was administered to each foal of the vaccinated mares by intravenous infusion and 50 mL by subcutaneous infusion at days 1, 5, 9, 13, and 17 after the challenge. HI plasma was not given to the foals of unvaccinated mares.

2.3. Laboratory Tests {#sec2.3}
---------------------

Blood samples were obtained from the challenged foals to determine the presence of anti-*R. equi* specific antibodies using a ELISA on the challenge day (day 0) and on days 10 and 20, to measure the interleukin-4 (IL-4) and interferon gamma (IFN-*γ*) concentrations on days 0, 1, 10, 20, and 30 and for complete blood count and blood gas analysis on days 0, 1, 5, 10, 14, 20, and 30 \[[@B25]\]. BALF samples were taken by passing a nasotracheal tube and in fusing 20 mL of sterile saline solution to bacterial culture and measure total cell count (TCC) on days 0, 1, 5, 10, 14, 20, and 30 \[[@B25], [@B26]\]. BALF samples were collected according to the method described by Mansmann and Knight \[[@B27]\] and Higuchi et al. \[[@B28]\]. The IL-4 and IFN-*γ* levels were measured using the Horse IL-4 ELISA kit (product code CSB-E14223Hs \[96 T\], Cusabio, Wuhan, Hubei, China) and Equine IFN-*γ* ELISA kit (ALP) (product code 3117-1A-6, MabTech, Thomastown, VIC, Australia) according to the manufacturer\'s instructions. The optimal dilutions of the serum samples, conjugate, substrate, and concentration of the coating antigen were standardized in our laboratory.

2.4. Clinical Examination {#sec2.4}
-------------------------

Fever (F), respiratory rate (R), pulse rate (P), cough, bronchial sounds, nasal discharge, and mucous membranes of foals were examined on days 0, 1, 5, 10, 14, 20, and 30. Clinical and respiratory system signs were defined as regular (0), mild (1), moderate (2), and severe (3) and normal (0), congested (1), and cyanotic (2) for mucous membranes.

2.5. Postmortem Examination {#sec2.5}
---------------------------

Foals were euthanized with an intravenous injection of a mixture of 100 mg of suxamethonium chloride and 22.5 mg sodium chloride (Lysthenon 2%, Fako, Turkey) 30 days after the challenge, and necropsy was performed. Macroscopic lesions in lungs and organs were scored according to [Table 1](#tab1){ref-type="table"}.

Samples from these organs were fixed in 10% formalin and embedded in paraffin wax blocks. Block sections of 5 µm thickness were stained with Luna \[[@B29]\]. All sections were evaluated under a light microscope.

2.6. Statistical Analysis {#sec2.6}
-------------------------

All statistical analyses were performed using the Student\'s *t*-test.

3. Results {#sec3}
==========

Two foals (numbers 5 and 7) of unvaccinated mares died before the challenge, and*R. equi*,*Streptococcus* sp., and*Corynebacterium* sp. were isolated from the lungs of these dead foals. In the place of the dead foals, two unvaccinated mares\' foals were included in the study. One of these foals died on day 7 and another on day 13 after the challenge.

Anti-*R. equi* antibody titer measured in vaccinated mares was higher than in the unvaccinated mares at birth by ELISA. In the foals of vaccinated mares, anti-*R. equi*antibody titer was determined to be 1/1600 of the maximum after the administration of hyperimmune plasma, and 1/200 titer was also determined in control foals ([Table 2](#tab2){ref-type="table"}).

The IL-4 concentration was measured to have a mean of \<16 pg/mL at days 0, 10, and 20 and a mean of 80 pg/mL at day 30 in foals of the vaccinated group, as well as a mean of 32 pg/mL in control foals. IFN-*γ* concentration increased on day 10 compared to the challenge day in both vaccine and control groups. By day 20, the control group remained stable, while the vaccine group exhibited doubling. By day 30, it increased in both groups but was measured to be 4.1-fold more in the vaccine group than in the control group ([Table 3](#tab3){ref-type="table"}).

The reisolation rate of*R. equi*from BALF samples was determined to have increased by day 10, decreased by day 20, and increased again by day 30 in the vaccinated and HI plasma-administered group. An increase was observed in the control group compared to day 1 ([Table 4](#tab4){ref-type="table"}, [Figure 1](#fig1){ref-type="fig"}).

A decrease in the concentration of pO2 and SO2 in the vaccine group was observed on day 5. The concentration of pCO2 and tCO2 increased, while the concentration of SO2 decreased on day 10. A decrease in the concentration of pO2 and SO2 in the control group was observed on day 30 (*P* \< 0.05) ([Table 6](#tab6){ref-type="table"}).

An insignificant (*P* \> 0.05) increase was observed in WBC concentration in both the control and vaccine group during the study period. Significant (*P* \< 0.05) differences were determined in percentages of LYM, MON, and GRAN concentration. The RBC concentration decreased significantly (*P* \< 0.05) on days 14 and 30 ([Table 6](#tab6){ref-type="table"}).

TCC of BALF and lung scores had increased in both groups by day 14 ([Table 5](#tab5){ref-type="table"}). These increases were statistically significant (*P* \< 0.05) in the control group, yet insignificant (*P* \> 0.05) in the vaccine group.

The clinical and lung auscultation findings indicate that clinical signs commenced on day 5 and increased until day 10 in both groups. In the vaccine group, however, it began to decrease after day 10 and because of the sepsis two foals died on days 7 and 15 in the control group.

The mean of total lesion scores of the organs and tissue was determined to be 78 in control group and 22 in the vaccine group. According to pathological findings, the severity of*R. equi* pneumonia and lesion scores of the organs and tissue was observed 3.54-fold less in the vaccinated and HI plasma-administered foals compared to the control foals ([Table 7](#tab7){ref-type="table"}, [Figure 2](#fig2){ref-type="fig"}).

4. Discussion {#sec4}
=============

Cell-mediated immunity is thought to play an important role in eliminating the facultative intracellular pathogen from foals, yet humoral immunity seems to be critically involved in the early protection in young foals. Foals are the most susceptible to the effects of virulent organisms when maternal antibody levels wane \[[@B30], [@B31]\]. The passive transfer of immunity plays a critical role in the foals\' resistance to a variety of infectious agents. Due to the epitheliochorial placentation of equines, foals must obtain all of their maternally derived antibodies by ingesting colostrum \[[@B10]\]. The lowest circulating antibody titers in foals appear from 1 to 6 months via the combined effects of waning maternally derived antibodies and low endogenous antibody production \[[@B32]\]. As a result, foals are susceptible to*R. equi* pneumonia during this period. Due to age-dependent susceptibility to*R. equi*, foals need to develop anti-*R. equi*immunity shortly after birth \[[@B25]\].

Since*R. equi* lives within macrophages, it resists many common antibiotics, and antibiotics-based therapy is prolonged, expensive, possibly associated with adverse effects, and inconsistently successful \[[@B33]\].

Studies investigating the active immunization of mares as a means of enhancing the passive transfer of virulent*R. equi*antibodies in colostrum and protecting foals from*R. equi* pneumonia have yielded mixed results. Solo vaccination of mares has not proven protective against*R. equi*pneumonia in foals, despite a significant increase in a colostral-specific antibody \[[@B14], [@B34]\]. Martens et al. \[[@B34]\], Madigan et al. \[[@B35]\], and Varga et al. \[[@B36]\] did not observe protection in foals against*R. equi*pneumonia after mare vaccination. Moreover, Hines et al. \[[@B31]\] reported that immunoglobulin in mares may not be efficiently transferred via colostrum. However, according to other researchers, passive antibody transfer from ingested colostrum was found to be associated with protection against*R. equi* in foals normally hypogammaglobulinemic at birth \[[@B11], [@B12], [@B14], [@B15]\]. Immunization of pregnant mares with virulent*R. equi* and VapA protein antigen associated with a water-based nanoparticle adjuvant as a candidate vaccine developed a higher serum IgG and opsonic activity, which resulted in passive antibody-mediated protection of foals \[[@B14]\]. Muscatello \[[@B17]\] reported that the protective effect was associated with an increase in the opsonic capacity of polymorphonuclear leucocytes against virulent*R. equi* in foals from immunized mares.

Martens et al. \[[@B37]\] were the first to show the immunoprophylactic capacity of specific hyperimmune plasma in an experimental model of*R. equi* pneumonia in foals. Other researchers have reported a reduction in foal morbidity and mortality due to*R. equi* as a result of HI plasma administration \[[@B14], [@B35], [@B37]--[@B39]\]. However, several other studies report no protective effects of HI plasma \[[@B11], [@B12], [@B40]\].

According to our results, the immunization of pregnant mares with a*R. equi* vaccine candidate and the administration of the anti-*R. equi* HI plasma in vaccinated mares\' foals proved to have protective effects during experimental*R. equi* infection. The clinical signs of pneumonia were significantly delayed, and the reisolation rate of*R. equi*from BALF samples decreased. The natural mortality rate due to*R. equi* infection was less than 50% in these foals compared to the controls. The severity of*R. equi* pneumonia and lesion scores of the organs and tissue determined 3.54-fold less than control foals.

The protective components of HI plasma are not completely known. Antibodies to Vap proteins, specifically VapA, appear to be crucially important \[[@B17]\]. It has been reported that there is no correlation between the total serum IgG levels and concentration of the specific anti-*R. equi* antibody \[[@B34], [@B35]\]. The phagocytic ability of foal neutrophils has been found comparable to adults, but the lymphocyte stimulation response alone did not influence the course of*R. equi* infection, while the opsonic ability of foal serum was found to be a limited factor for phagocytosis from the ages of 1 to 6 weeks \[[@B41], [@B42]\]. Phagocytic activity of foal neutrophils was found to improve when mixed with adult serum or plasma \[[@B43]\], which may be related to unknown, nonspecific immune factors provided by HI plasma and normal adult equine plasma that are absent from colostrum, such as fibronectin, complement, and cytokines \[[@B12], [@B40], [@B44]\]. The effectiveness of HI plasma is likely to be affected by the dosage, timing of administration, innate immune system competence, management conditions, and number of virulent bacterin in the environment \[[@B45]\].

Cytokines IFN-*γ* and IL-4 are major macrophage and neutrophil-activating factors, as well as upregulated microbial killing pathways \[[@B46]\]. It is reported that newborn foals had a deficiency of IFN-*γ*/IL-4 and levels not reaching adult status until approximately 4 months of age \[[@B47]\]. Reduced IFN-*γ* and IL-4 expression have a limited killing capacity of phagocytes in young foals \[[@B47], [@B48]\]. In our study, the IFN-*γ* and IL-4 concentration measured 4.1-fold and 2.5-fold more in the foals of vaccinated mares and HI plasma-administered, respectively, compared to the control foals.

According to changes in blood gases of foals, it was observed that lung ventilation in the challenge group had been affected by day 5, intensified after day 10, and continued to increase during the study period.

The important decrease (*P* \< 0.05) of the RBC concentration on days 14 and 30 and significant differences (*P* \< 0.05) of the MCV and RDW values in the vaccine and control group were evaluated as microcytic/normocytic-normochromic-regenerative anemia which was interpreted as a response to emerging infectious.

Given the decrease in the number in the controls, BALF-TCC parameters were detected as statistically insignificant (*P* \> 0.05).

According to clinical scores and laboratory findings, the effect of infection in the vaccine group began on day 5, increased from day 9 to 14, and was constant from days 20 to 30. The effect of infection was similar in the control group, though the clinical findings increased from days 7 to 15, and two foals died of sepsis during this latter period. These findings show that resistance to infection was low in the control group.

As yet there is no licensed vaccine for the prevention of*R. equi*. However, on January 27, 2011, Intervet/Schering-Plough Animal Health announced that a vaccine against*Rhodococcus equi* infection in foals had entered the final stages of development \[[@B49]\].

5. Conclusions {#sec5}
==============

Our results indicate that the immunization of pregnant mares with a water-based nanoparticle mineral oil adjuvanted (IMS 3012) inactive bacterin and VapA and the administration of HI plasma in foals of these mares effectively protect foals against*R. equi*challenge. Foals are born into the*R. equi* contaminated environment due to mares carrying the*R. equi* in their intestines.*R. equi* infection can be controlled by both the mares\' vaccination and anti-*R. equi*-HI plasma administration in foals of such dams.
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![Reisolation rate of*R. equi* from foals\' BALF samples (CFU/mL).](TSWJ2014-480732.001){#fig1}

![(a) Normal lung in a foal of vaccine group, (b) pyogranuloma formation in the*R. equi* inoculated left lung of a control foal (arrow), (c) pyogranuloma in lung, and (d) infarction areas in kidney of control foals (arrows).](TSWJ2014-480732.002){#fig2}

###### 

Macroscopic lesions scores in lungs and organs after necropsy.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Postmortem Lesion Scores                                                                                                                                                                                                                                                                                                                                                                                                       
  -------------------------- ----------------- ------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------
  Lung                       Without lesions   With 2 to 3 small pyogranulomas or large abscess formation limited to only one lobe of the lung and focal consolidation   With four to five pyogranulomas limited to two lobes of the lung multifocal consolidation and large abscess formation   With a large number of differently sized pyogranulomas limited to three lobes or between the right and left lobes of the lung   With military or differently sized pyogranulomas spread over all lobes of the lung

                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Lymph \                    Without lesions   With slight growth                                                                                                        With mild growth                                                                                                        Overgrown and with limited pus foci of the cross-sectional surface                                                              Overgrown and purulent
  node                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Heart                      Without lesions   With slight paleness                                                                                                      With a wide area of paleness in the epicardium and endocardium or pyogranuloma                                          With a wide area of paleness in the cross-sectional area or a few pyogranulomas                                                 With a wide area of paleness in the cross-sectional area or several pyogranulomas

                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Liver                      Without lesions   Slightly enlarged and congested                                                                                           Enlarged and mottled appearance or with pyogranuloma                                                                    With numerous pyogranulomas in the cross-sectional area and under the capsule                                                   With pyogranulomas spread over the entire surface and the cross-sectional area

                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Kidney                     Without lesions   Slightly enlarged                                                                                                         Enlarged kidneys and mottled appearance                                                                                 Enlarged kidneys and with pyogranuloma in the cross-sectional area and infarction area                                          Enlarged kidneys and with numerous pyogranulomas in the cross-sectional area and infarction area

                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Spleen                     Without lesions   Slightly enlarged                                                                                                         Overgrown and with pyogranuloma in the cross-sectional area                                                             Overgrown and with a few pyogranulomas in the cross-sectional area                                                              Overgrown and with numerous pyogranulomas in the cross-sectional area
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Anti-*R. equi* antibody ELISA titer of vaccinated and unvaccinated mares and challenged foals.

  Mare group     Mare number   ELISA titer at birth   Foal group            Foal number   ELISA titer after challenge            
  -------------- ------------- ---------------------- --------------------- ------------- ----------------------------- -------- --------
  Vaccinated     1             1/12800                Vaccine + HI plasma   1             1/800                         1/1600   1/1600
  2              1/6400        2                      1/100                 1/400         1/800                                  
  3              1/3200        3                      1/800                 1/1600        1/1600                                 
  4              1/6400        4                      1/400                 1/800         1/800                                  
                                                                                                                                 
  Unvaccinated   5             Negative               Control               5             0                             1/200    ∗
  6              1/200         6                      0                     Negative      1/200                                  
  7              Negative      7                      0                     ∗             ∗                                      
  8              Negative                             8                     0             Negative                      1/200    

\*Because foals died, ELISA titer was not measured on these days.

###### 

IL-4 (pg/mL) and IFN-*γ* (ng/mL) concentration in challenged foals.

  Foal group            Foal number         Day 0             Day 10            Day 20         Day 30
  --------------------- ------------------- ----------------- ----------------- -------------- --------------
  Vaccine + HI plasma   1                   \<16/\<0.01       \<16/0.01         \<16/0.02      **128/0.05**
  2                     \<16/\<0.005        \<16/0.005        \<16/0.01         **128/0.05**   
  3                     \<16/\<0.005        \<16/0.005        \<16/0.01         32/0.05        
  4                     \<16/\<0.005        \<16/0.005        \<16/0.01         32/0.05        
  Mean                  **\<16/\<0.0075**   **\<16/0.0075**   **\<16/0.015**    **80/0.05**    
                                                                                               
  Control               5                   \<16/\<0.005      \<16/0.005        ∗              ∗
  6                     \<16/\<0.005        \<16/0.005        \<16/0.001        32/0.005       
  7                     \<16/\<0.005        ∗                 ∗                 ∗              
  8                     \<16/\<0.005        \<16/0.005        \<16/0.01         32/0.02        
  Mean                  **\<16/\<0.005**    **\<16/0.005**    **\<16/0.0055**   **32/0.012**   

\*Because the foals died, IL-4 and IFN-*γ* concentration were not measured on these days.

###### 

Reisolation rate of *R. equi* from BALF samples (CFU/mL) and lung samples (CFU/gr) after necropsy in foals.

  Foal group            Foal number   Day 0       Day 1        Day 10       Day 20       Day 30    Necropsy
  --------------------- ------------- ----------- ------------ ------------ ------------ --------- ----------
  Vaccine + HI plasma   1             0           65000        135          1400         140       50
  2                     0             1000        55           1220         0            21000     
  3                     0             1300        120          12700        0            0         
  4                     0             2600        195          90000        170000       ∗∗        
  Mean                  **0**         **17475**   **126**      **26330**    **42535**              
                                                                                                   
  Control               5             0           19000        800          died         ---       ∗∗
  6                     0             4100        3600         1300000      1100000      320000    
  7                     0             5500        Died         ---          ---          ∗∗        
  8                     0             83000       640000       2300         100000       3250000   
  Mean                  **0**         **27900**   **214666**   **651150**   **600000**             

\*\*Too many to count.

###### 

Total cell count (TCC) of BALF samples, clinical signs, respiratory system signs, mucous membrane scores, and temperature of foals.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                             Foal group           Day 0                Day 1                Day 5                Day 10                  Day 14                 Day 20                  Day 30
  -------------------------- -------------------- -------------------- -------------------- -------------------- ----------------------- ---------------------- ----------------------- -------------------
  BALF-TCC                   Control              300.00 ± 57.74       300.00 ± 57.74       300.00 ± 57.74       300.00 ± 57.74          466.67 ± 266.67        8800.00 ± 8400.00       1500.00 ± 1100.00

  Vaccinated                 **300.00 ± 57.74**   **300.00 ± 57.74**   **300.00 ± 57.74**   **300.00 ± 57.74**   **2600.00 ± 1116.54**   **1000.00 ± 258.20**   **1950.00 ± 1040.43**   

                                                                                                                                                                                        

  Clinical score             Control              0.00 ± 0.00          0.00 ± 0.00          0.00 ± 0.00          0.00 ± 0.00             1.00 ± 1.00            0.00 ± 0.00             0.00 ± 0.00

  Vaccinated                 **0.00 ± 0.00**      **0.00 ± 0.00**      **0.00 ± 0.00**      **0.00 ± 0.00**      **0.00 ± 0.00**         **0.00 ± 0.00**        **0.00 ± 0.00**         

                                                                                                                                                                                        

  Respiratory system score   Control              0.00 ± 0.00          0.00 ± 0.00          **0.00**± 0.00 B     1.00 ± 0.58             0.67 ± 0.33 B          0.00 ± 0.00 B           0.00 ± 0.00 B

  Vaccinated                 **1.00 ± 0.00**      **0.00 ± 0.00**      **1.25 ± 0.48 A**    **2.00 ± 0.00**      **0.275 ± 0.25 A**      **2.75 ± 0.25 A**      **2.75 ± 0.25 A**       

                                                                                                                                                                                        

  Mucous\                    Control              0.00 ± 0.00          0.00 ± 0.00          0.00 ± 0.00          0.00 ± 0.00             0.33 ± 0.33            0.00 ± 0.00             0.00 ± 0.00
  membrane score                                                                                                                                                                        

  Vaccinated                 **0.00 ± 0.00**      **0.00 ± 0.00**      **0.00 ± 0.00**      **0.00 ± 0.00**      **0.00 ± 0.00**         **0.00 ± 0.00**        **0.00 ± 0.00**         

                                                                                                                                                                                        

  Temperature                Control              38.3 ± 0.12          38.43 ± 0.11         38.05 ± 0.23         27.90 ± 9.31            37.87 ± 0.24           38.20 ± 0.20            38.45 ± 0.05

  Vaccinated                 **38.13 ± 0.13**     **38.33 ± 0.22**     **38.50 ± 0.11**     **38.45 ± 0.06**     **38.05 ± 0.16**        **38.60 ± 0.07**       **38.60 ± 0.07**        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Complete blood count and blood gas analysis results of foals.

  Foal group               Day 0                Day 1                Day 5                Day 10                Day 14               Day 20               Day 30               
  ------------------------ -------------------- -------------------- -------------------- --------------------- -------------------- -------------------- -------------------- ----------------
  pH (7.34--7.43)          Control              7.45 ± 0.02          7.41 ± 0.02          7.43 ± 0.02           7.35 ± 0.03          7.42 ± 0.01          7.45 ± 0.02          7.40 ± 0.02
  Vaccinated               **7.43 ± 0.01**      **7.42 ± 0.01**      **7.41 ± 0.01**      **7.41 ± 0.01**       **7.41 ± 0.01**      **7.39 ± 0.01**      **7.42 ± 0.01**      
                                                                                                                                                                               
  pCO2 (38--48 mmHg)       Control              37.50 ± 1.19         42.25 ± 0.75         45.75 ± 1.93          52.75 ± 2.78 A       47.33 ± 2.73         40.50 ± 1.50         47.00 ± 3.00
  Vaccinated               **40.00 ± 1.78**     **42.00 ± 1.47**     **42.00 ± 0.41**     **40.25 ± 125 B**     **42.00 ± 2.74**     **45.00 ± 3.14**     **40.50 ± 1.26**     
                                                                                                                                                                               
  pO2 (37--56 mmHg)        Control              35.00 ± 2.12         35.00 ± 2.12         36.75 ± 1.55 A        33.00 ± 1.35         32.00 ± 2.08         38.00 ± 4.00         34.00 ± 1.01 B
  Vaccinated               **37.25 ± 3.71**     **33.50 ± 2.63**     **29.00 ± 1.91 B**   **36.25 ± 1.75**      **53.75 ± 21.46**    **33.75 ± 2.29**     **41.25 ± 1.38A**    
                                                                                                                                                                               
  tCO2                     Control              26.98 ± 1.26         28.03 ± 1.21         31.53 ± 1.81          30.53 ± 0.61 A       31.87 ± 1.18         29.05 ± 0.55         30.20 ± 0.90
  Vaccinated               **27.85 ± 0.45**     **28.35 ± 0.73**     **28.05 ± 0.29**     **26.75 ± 0.84 B**    **27.95 ± 1.47**     **54.15 ± 27.30**    **27.65 ± 0.57**     
                                                                                                                                                                               
  SO2 (\>60 mmHg)          Control              70.00 ± 2.48         67.00 ± 3.37         71.50 ± 1.32 A        71.50 ± 1.32 A       62.67 ± 4.67         74.50 ± 4.50         65.00 ± 1.00 B
  Vaccinated               **71.25 ± 6.70**     **64.75 ± 4.87**     **55.50 ± 4.29 B**   **55.50 ± 4.29 B**    **71.50 ± 9.50**     **53.90 ± 7.42**     **77.75 ± 1.38 A**   
                                                                                                                                                                               
  WBC (5--12 × 10^3^)      Control              7.08 ± 1.01          7.68 ± 1.31          7.32 ± 1.16           7.02 ± 1.12          5.65 ± 1.66          4.64 ± 0.37          10.53 ± 2.61
  Vaccinated               **6.66 ± 0.87**      **5.86 ± 0.33**      **8.82 ± 1.29**      **8.86 ± 0.87**       **8.60 ± 0.66**      **26.90 ± 15.77**    **10.33 ± 1.57**     
                                                                                                                                                                               
  LYM (% 20--40)           Control              15.60 ± 2.46 B       15.70 ± 0.90 B       22.65 ± 2.41          22.80 ± 1.86 B       29.13 ± 11.52        36.85 ± 14.75        17.50 ± 10.00
  Vaccinated               **35.60 ± 3.98 A**   **30.65 ± 2.23 A**   **34.63 ± 6.43**     **36.75 ± 4.88 A**    **37.83 ± 4.26**     **27.11 ± 6.51**     **31.85 ± 3.40**     
                                                                                                                                                                               
  MON (% 2--8)             Control              1.40 ± 0.12 B        1.68 ± 0.11          3.55 ± 0.13           3.43 ± 0.77          3.67 ± 1.22          3.50 ± 0.90          1.60 ± 0.70 A
  Vaccinated               **2.75 ± 0.45 A**    **2.73 ± 0.52**      **3.00 ± 0.48**      **3.05 ± 0.46**       **3.58 ± 0.33**      **8.00 ± 5.90**      **2.53 ± 0.46**      
                                                                                                                                                                               
  GRAN (% 50--70)          Control              83.00 ± 2.55 A       82.63 ± 0.92 A       73.80 ± 2.46          73.78 ± 2.32         67.20 ± 12.72        59.65 ± 15.65        80.90 ± 10.70
  Vaccinated               **61.65 ± 3.70 B**   **64.75 ± 4.87 B**   **62.38 ± 6.69**     **60.20 ± 5.10**      **58.60 ± 4.42**     **49.43 ± 16.35**    **65.63 ± 3.78**     
                                                                                                                                                                               
  RBC (7--13 × 10^6^)      Control              8.87 ± 0.48          9.28 ± 0.89          9.27 ± 0.39           9.10 ± 0.71          8.10 ± 0.64 B        9.01 ± 1.16          8.05 ± 0.24 B
  Vaccinated               **9.65 ± 0.32**      **11.30 ± 1.02**     **10.22 ± 0.34**     **10.03 ± 0.22**      **9.89 ± 0.26 A**    **25.16 ± 15.82**    **9.98 ± 0.27 A**    
                                                                                                                                                                               
  MCV (35--60 fl)          Control              32.63 ± 0.29 A       32.83 ± 0.24 A       32.78 ± 0.71 A        34.48 ± 0.47 A       33.23 ± 0.91         32.70 ± 0.90         32.00 ± 1.90
  Vaccinated               **29.43 ± 1.14 B**   **29.95 ± 0.76 B**   **29.50 ± 0.93 B**   **29.30 ± 0.99 B**    **30.85 ± 0.92**     **26.24 ± 5.43**     **30.50 ± 0.68**     
                                                                                                                                                                               
  HCT (% 32--53)           Control              28.85 ± 1.39         30.43 ± 3.04         30.30 ± 1.10          31.38 ± 2.66         26.77 ± 1.39         29.30 ± 3.00         25.65 ± 0.75 B
  Vaccinated               **28.43 ± 1.98**     **33.70 ± 2.90**     **30.10 ± 1.11**     **29.35 ± 1.42**      **30.43 ± 0.92**     **29.18 ± 0.71**     **30.33 ± 0.50 A**   
                                                                                                                                                                               
  MCHC (30--42 g/dL)       Control              39.75 ± 0.43         36.18 ± 2.50         39.63 ± 0.26          36.78 ± 0.86         37.43 ± 0.45         38.85 ± 0.15         40.50 ± 1.20
  Vaccinated               **39.50 ± 1.67**     **40.60 ± 0.94**     **43.65 ± 3.07**     **41.73 ± 1.15**      **37.93 ± 0.61**     **38.40 ± 0.93**     **38.70 ± 1.09**     
                                                                                                                                                                               
  RDW (8--12)              Control              14.45 ± 0.10         14.60 ± 0.47 B       14.30 ± 0.27 B        14.10 ± 0.43 B       14.13 ± 0.29         15.05 ± 0.85         16.65 ± 0.65
  Vaccinated               **15.40 ± 0.54**     **16.00 ± 0.31 A**   **15.85 ± 0.37 A**   **16.18 ± 0.55 A**    **16.30 ± 0.83**     **16.70 ± 1.00**     **17.15 ± 0.84**     
                                                                                                                                                                               
  HB (11--17 g/dL)         Control              11.48 ± 0.47         10.83 ± 0.59         12.03 ± 0.51          11.53 ± 0.86         10.03 ± 0.64         11.40 ± 1.20         10.40 ± 0.00
  Vaccinated               **11.18 ± 0.55**     **13.68 ± 1.12**     **12.40 ± 0.44**     **12.23 ± 0.43**      **11.55 ± 0.39**     **11.23 ± 0.44**     **11.75 ± 0.48**     
                                                                                                                                                                               
  THR (100--400 m/mm^3^)   Control              278.50 ± 87.36       330.50 ± 87.36       287.00 ± 44.53        238.50 ± 29.83 B     171.33 ± 30.69       240.00 ± 37.00       241.50 ± 8.50
  Vaccinated               **248.50 ± 30.01**   **317.00 ± 40.26**   **410.00 ± 49.83**   **384.50 ± 9.56 A**   **244.00 ± 19.20**   **341.50 ± 26.38**   **279.00 ± 25.65**   

###### 

Lesion scores of the organs and tissue according to pathological findings.

  Foal group            Foals number   Lung   Bronchial LN   Mediastinal LN   Heart   Liver   Kidney   Spleen   Cecum LN   Total foal score   Total group score   Mean group score
  --------------------- -------------- ------ -------------- ---------------- ------- ------- -------- -------- ---------- ------------------ ------------------- ------------------
  Vaccine + HI plasma   1              1      1              0                0       0       0        0        2          4                  ** 22**             ** 5.5**
  2                     0              2      2              0                0       0       1        1        6                                                 
  3                     1              1      1              0                0       0       0        0        3                                                 
  4                     3              3      2              0                0       0       0        1        9                                                 
                                                                                                                                                                  
  Control               5              4      4              4                4       4       4        4        4          32                 ** 78**             ** 19.5**
  6                     3              1      1              2                0       0       0        1        8                                                 
  7                     4              4      4              4                4       4       4        4        32                                                
  8                     3              1      1              0                0       0       0        1        6                                                 

[^1]: Academic Editors: T. Betakova, V. Fedorenko, Y. Mu, Z. Shi, and H. Zaraket
